Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010

Abstract

We found a significant increase in overall survival, PFS, and survival after recurrence after 2004, likely due to improvements in surgical techniques, introduction of the Stupp protocol as a first-line treatment, and new standard protocols for second-line chemotherapy and radiosurgery after tumor recurrence. In both cohorts, reoperation after tumor recurrence did not improve survival.

Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients

“…We compared our data with the analysis of “Cohort II” from a retrospective analysis of therapy response performed by Nava et al [29]. Cohort II was composed of 746 patients with histologically confirmed primary GB who were diagnosed and treated with the Stupp protocol [1] as a firstline treatment, and new standard protocols for second-line chemotherapy and radiosurgery after tumor recurrence.…”

Therapeutic options in recurrent glioblastoma—An update

“…A prospective registry study of 764 patients with glioblastoma analyzed over a 7-year period (2004)(2005)(2006)(2007)(2008)(2009)(2010) with one third of patients reoperated at recurrence did not suggest a benefit of repeat surgery (HR 1.02), however, no detailed patient stratification for prognostic variables was available [28]. Similarly, in a meta-analysis of 8 prospective phase I and II trials comprising 300 patients with recurrent glioblastoma repeat surgery was not an independent predictor for PFS and OS [29].…”

First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma

“…The current options include further surgery, second line chemotherapy and stereotactic radiosurgery [24]. Therefore, there is a clear need to identify novel therapeutic approaches to improve outcomes [25].…”